Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

@article{Qi2013PaclitaxelbasedVD,
  title={Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials},
  author={W. Qi and Z. Shen and F. Lin and Y. Sun and Da-liu Min and L. Tang and Ai-na He and Y. Yao},
  journal={Current Medical Research and Opinion},
  year={2013},
  volume={29},
  pages={117 - 125}
}
  • W. Qi, Z. Shen, +5 authors Y. Yao
  • Published 2013
  • Medicine
  • Current Medical Research and Opinion
  • Abstract Objectives: Docetaxel and paclitaxel show significant clinical activity in metastatic breast cancer (MBC) and have been approved for MBC by the U.S. Food and Drug Administration, but it is still unclear whether a paclitaxel-based regimen improves outcomes over a docetaxel-based regimen in patients with MBC. We therefore performed a meta-analysis of randomized controlled trials to compare the safety and efficacy of these two regimens in MBC. Methods: We systematically searched for… CONTINUE READING
    23 Citations
    Taxane-containing regimens for metastatic breast cancer.
    • 49
    Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study
    • 8
    Paclitaxel-based regimens as first-line treatment in advanced gastric cancer
    • 12
    Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis.
    Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
    • 3
    Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer
    • 11

    References

    SHOWING 1-10 OF 40 REFERENCES
    Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    • 220
    Paclitaxel and docetaxel in the treatment of breast cancer.
    • 49
    Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
    • S. Jones, J. Erban, +12 authors P. Ravdin
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2005
    • 450
    Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
    • E. Winer, D. Berry, +14 authors L. Norton
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 194